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 That the fundamental aspects of heredity should have turned out 
to be so extraordinarily simple supports us in the hope that nature 
may, after all, be entirely approachable. Her much-advertised 
inscrutability has once more been found to be an illusion due to 
our ignorance. This is encouraging, for, if the world in which we live 
were as complicated as some of our friends would have us believe, we 
might well despair that biology could ever become an exact science. 
(Thomas Hunt Morgan, 1856 - 1945[1])
Since antiquity, the hereditary nature of health and disease has 
been appreciated. For instance, recognition that epilepsy, the ‘sacred 
disease’, was not truly sacred, but may have its origins in heredity, was 
described in Hippocratic times. Unravelling these heritable factors 
has, however, proven to be an ongoing challenge. For most medical 
conditions, the phenotype we see is the endpoint of multiple genetic 
and environmental factors; this includes many of the conditions seen 
every day in a general practice, such as type 2 diabetes, hypertension, 
asthma and most cancers. These multifactorial or ‘complex’ disorders 
cluster in families who share a genetic background but do not obey 
the rules of Mendelian inheritance. Individually, each genetic variant 
(GV) typically makes a small contribution and cannot be used 
diagnostically, but added to each other can powerfully affect the 
overall phenotype. 
Studying the function of the gene product and interactions with 
other genetic modifiers and the environment can lead to new ways of 
thinking about therapeutic targets and interventions. Identification 
of both genetic and environmental factors in common conditions 
that are major contributors to the burden of disease is leading 
the way to more accurate risk stratification that can influence the 
implementation of appropriate health services. 
New genetic and genomic technologies that have emerged since the 
turn of the century, alongside the exponential growth in information 
technology and data handling, have driven the discovery of genes, 
genetic variation and genetic association. This, in turn, has resulted 
in much greater insight into physiology and function and what 
can and does go wrong in biology. Until recently, most of the 
attention was focused on the exome – the protein-coding regions 
of our genome that make up only 1 - 2% of our DNA. However, the 
reduction in sequencing cost and improvements in handling big 
data have recently redirected much of the focus to the remainder 
of the genome and on how our DNA is controlled. What continues 
to surprise is how different we are, and this has compounded some 
of the difficulties in interpretation of DNA GVs that vary from the 
‘reference’ genome – a work in progress, which is constantly updated 
and maintained through international collaboration. A particular 
challenge for Africa, where mankind first evolved, is that genetic 
variation is greater in African populations, while reference datasets 
are fewer. Clearly, Africa needs its own genome revolution.
So where to from here? On the one hand, medical genetics has 
long been perceived to be the study of ‘rare’ or unusual disorders or 
diseases (collectively, of course, not rare at all). On the other hand, 
genomic medicine means that every healthcare professional will 
need a working knowledge of the genome and some understanding 
of its complexity. There is so much known, but also so much to learn, 
that caution should still be exercised in interpreting genetic findings 
out of context, as nothing in our DNA acts in isolation. Genomic 
information is accumulating at a rapid rate; therefore, what we knew 
yesterday may be very different to what we know tomorrow. Rapid 
advances, coupled with easy access to information on the internet, 
have created expectation and anxiety in healthcare professionals 
and the public alike. Direct-to-consumer DNA-based testing is 
freely available and marketed for indications as wide ranging as 
cancer predisposition testing, sex determination of an embryo and 
personality or sporting ability associations. No wonder our patients 
see their genome as a crystal ball.
New findings undoubtedly drive us closer and closer to the goal 
of precision medicine, but the clinician will continue to play an 
essential role in making sense of the knowledge generated by the new 
‘omics’. More knowledge means more power to control our health 
and our environment, but brings new ethical dilemmas that need 
to be considered while balancing the needs of the collective and the 
individual.
Since the Hippocratic era, the story of medicine has been one of 
ever more sophisticated phenotyping: these are the symptoms of 
diabetes; these are the signs of diabetes; this is how diabetes affects 
the skin, the brain, the eyes, the kidney and the heart; these are the 
molecular mechanisms that underlie diabetic retinopathy, diabetic 
nephropathy and diabetic cardiomyopathy. Modern genetics now 
has a historic opportunity to complete the symmetry of this equation 
by bringing parallel genotyping to the traditionally phenotypic 
endeavour of clinical medicine.[2]
Biology and clinical medicine are amid a remarkable revolution – 
technical advances in DNA sequencing have given us access to the 
molecular code governing everyone’s unique phenotype, including 
disease susceptibility and drug sensitivity. The compelling promise 
of truly personalised medicine spurred the quest for methods to 
achieve precision genomic manipulation. In an interesting twist 
of scientific fate, basic research on an adaptive immune system in 
bacteria led to the breakthrough genomic engineering technology 
known as clustered regularly interspaced short palindromic repeats 
(CRISPR)-associated protein 9 (Cas9) (CRISPR-Cas9). Experiments 
focused on understanding how bacteria acquire resistance to viruses, 
using genomic loci known as CRISPR, uncovered the activity of 
the CRISPR-associated RNA-guided DNA-cleaving enzyme, Cas9. 
Cas9 generates double-stranded DNA breaks at sites matching 
the sequence of a guide RNA molecule that was designed in the 
laboratory to include features necessary for both Cas9 binding 
and DNA recognition.[3] These new technologies have made the 
possibility of genome editing in humans a reality. 
In the context of rapid developments in medical genetics and 
genomics, what does the future of medicine look like?
Precision medicine (PM). PM is an approach that proposes the 
customisation of healthcare, with medical diagnostics, decisions, 
therapies, practices and products tailored to the individual patient. 
Diagnostic testing employs molecular genetics, molecular and cellular 
biology techniques and multimodal imaging and analytics. The 
underlying principle of PM is not new, e.g. for more than a century, 
transfusion patients have been matched with donors according 
to blood type. Advances in genetics and genomics and growing 
availability of health data, make PM a clinical reality for many. 
Increasingly, artificial intelligence, the ability to handle big data and 
bioinformatics are providing a paradigm shift towards PM. 
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Genome engineering and editing. With the advent of precision 
genome editing, the ability to modify living organisms has proceeded 
with remarkable speed and breadth. Any application of this technology 
to the human germline must be tightly coupled to deliberate ethical 
consideration of the consequences, both scientific and social, of 
introducing heritable alterations to the human population. Recently, 
the US National Academy of Sciences and National Academy of 
Medicine released their report on recommendations for human 
genome editing.[4] The capacity to edit genes has existed for decades, 
and genetic modification is common practice in the laboratory. 
The heightened concern is that recent technological advances have 
enabled the precise editing of genomes at unprecedented speed and 
scale. Zinc-finger nucleases, transcription activator-like effector 
nucleases  (TALENs) and, now, the CRISPR-Cas9 system have 
revolutionised scientific discovery, which has direct implications for 
human disease.
Genetic variants of unknown significance (GVUS). It is likely 
that, with increasing human mutational analysis and genotyping, 
there will be an exponential increase in the number of GVUS. These 
will add increasing complexity in interpretation and explanation to 
patients and families. This scenario is likely to be exaggerated in 
African populations, for whom comprehensive reference genetic data 
sets do not currently exist.
High-throughput sequencing applied to the clinic. Modern 
sequen cing approaches have resulted in the rapid disappearance of 
the barriers to mutation identification in genetically heterogeneous 
disorders. Soon the ability to rapidly sequence all the genes known 
to be involved in disorders such as cardiomyopathy, long QT syn-
drome and retinitis pigmentosa will be at hand.
Pharmacogenomics. Even before clinical outcome data are 
available, the US Food and Drug Administration (FDA) has 
realised the importance of pharmacogenomics in clinical practice 
and has advised on genotypic guidance in warfarin dosing, a drug 
that is prescribed more than 100 million times annually globally. 
Currently few doctors know how to apply pharmacogenomic data 
in clinical practice. 
Complex databases to collect genotype/phenotype infor-
mation. Aided by modern bioinformatic approaches, the acquisition 
and interpretation of such information for patient care will become 
clearer for geneticists and clinicians.
Ethical, legal and social issues (ELSI). ELSI are likely to become 
much more prominent in academic and public discourse due to 
the increasing importance of genetic and genomic information for 
many aspects of human health and society. 
Genetic counsellors. The important role that genetic counsellors 
must play in educating patients and the lay public regarding aspects 
of genetic medicine will become increasingly obvious. Doctors will 
not be able to accomplish the integration of genetics into medicine 
on their own.
Human geneticists. It is likely that many more clinics will have 
a multidisciplinary nature, with human geneticists playing a much 
more collaborative role in partnership with doctors from different 
disciplines. 
This issue of CME, second in the series on genetics in medicine, 
contains 3 articles that reflect some of the complexity of genomic 
medicine and what the future of medicine may look like. Laing et al.[5] 
review the genetic contributions to the global increasing burden of 
cardiovascular disease, including both monogenic and more common 
multifactorial disorders. Ramesar[6] provides an introduction to 
epigenetics – how the genome is controlled and influenced by 
the environment to maintain the balance between stability and 
adaptability that is central to our ability to function. Finally, De Vries 
and Munung[7] remind us of the ethical challenges to consider as 
our deeply personal genetic information gets unpacked and shared, 
and places this discourse in a South African context, encouraging a 
pragmatic but thoughtful approach.
We hope this series gives you useful information on some aspects 
of genetics in medicine, as well as a glimpse into the future of genomic 
medicine in the 21st century. Similar to Thomas Hunt Morgan’s 
realisation, almost a century ago, that advances in understanding 
of genetics allow us to find nature to be 
‘entirely approachable’, we hope that this 
introduction to genetics provides you with 
a platform to better understand the biology 
of human physiology and function, as well 
as pathology.
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